Viking Therapeutics shares more than double on ‘statistically significant’ weight-loss trial results
US biotech group’s data suggests dominance of Novo Nordisk and Eli Lilly in the anti-obesity segment could be challenged in a few years
Source: FT.com - Drugs and Healthcare - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Eating Disorders & Weight Management | Obesity | Pharmaceuticals | Statistics | Weight Loss